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Objective: To assess satisfaction with the serum-free formulation of subcutaneous (sc) 
  interferon (IFN) beta-1a among patients with relapsing multiple sclerosis (MS).
Methods: Patients with relapsing MS who had been receiving sc IFN beta-1a for at least 
6 months, were transitioned to the new formulation, 44 µg three times weekly. Patients were 
randomized to preventative ibuprofen (400 mg 30–60 minutes prior to injection) or ibuprofen 
as needed (PRN) for 4 weeks. The primary endpoint was the ‘flu-like’ symptom (FLS) domain 
score of the validated Multiple Sclerosis Treatment Concern Questionnaire (MSTCQ).
Results: Of the 117 patients enrolled, 109 (93.2%) completed the study. Neither group’s 
MSTCQ FLS score showed a clinically meaningful change from baseline to week 4: mean ± SD 
changes were -1.1 ± 4.4 in the preventative ibuprofen group and 0.8 ± 3.6 in the ibuprofen PRN 
group. MSTCQ injection system satisfaction and global side-effect scores were unchanged; 
total and injection-site reaction scores improved moderately in both groups between baseline 
and week 4.
Conclusions: Results showed continued or increased levels of satisfaction with the new 
  formulation of sc IFN beta-1a. FLS occurring with the new formulation were generally mild 
and seldom sufficiently bothersome to require ibuprofen treatment.
Keywords: multiple sclerosis, tolerability, ibuprofen, flu-like symptoms
Background
Subcutaneous (sc) interferon (IFN) beta-1a (Rebif  ®, Merck Serono S.A. – Geneva, 
Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany), has been shown in 
randomized clinical trials to be effective in the treatment of relapsing forms of multiple 
sclerosis (MS) when administered at doses of 22 or 44 µg three times weekly (tiw).1–3
The original formulation of sc IFN beta-1a contains fetal bovine serum (FBS) and 
human serum albumin (HSA) as excipients. A new formulation of sc IFN beta-1a 
has been developed that is free from FBS and HSA. This formulation adjustment 
was made with the intention of reducing immunogenicity and improving the local 
tolerability of sc IFN beta-1a. These outcomes were assessed in an open-label study 
in which IFN beta treatment-naïve patients with relapsing MS (n = 260) received 
the new formulation of sc IFN beta-1a, 44 µg tiw, for 96 weeks.4 This study showed 
that the new formulation has an improved overall immunogenicity profile compared Patient Preference and Adherence 2010:4 128
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with historical data from patients treated with the original 
formulation of sc IFN beta-1a in the EVidence of Interferon 
Dose-response: European North American Comparative 
Efficacy (EVIDENCE) and Rebif ® vs Glatiramer Acetate 
in Relapsing MS Disease (REGARD) trials. Although the 
trial of the new formulation was not designed to assess effi-
cacy, relapses remained well controlled over the 96-week 
study period. Additionally, the proportion of patients 
  experiencing injection-site reactions (ISRs) was lower 
with the new formulation: ISRs were reported in 30.8% of 
patients treated with the new formulation, compared with 
85.8% in the EVIDENCE study and 41.2% in the REGARD 
study.5,6 ‘Flu-like’ symptoms (FLS) are known to be a com-
mon adverse event (AE) of IFN beta, particularly in the 
period shortly after treatment initiation:3,7–9 In this study, 
71.5% of IFN beta-naïve patients experienced FLS, com-
pared with 49.0% in the EVIDENCE study and 36.0% in 
the REGARD study. Almost all incidences were of mild or 
moderate severity and transient, and only 8.5% of patients 
were experiencing FLS at the 96-week visit. In most patients, 
FLS can be managed by concomitant use of nonsteroidal 
anti-inflammatory drugs (NSAIDs) such as ibuprofen;10 
however, the use of NSAIDs for the management of FLS was 
permitted but not mandated in this trial. As such, prophylactic 
medication to prevent FLS was administered by only 38% 
of patients on study day 1, and the authors commented that 
increasing this proportion may have reduced the incidence of 
FLS.4 Given that FLS are common with IFN-beta treatment 
and that they can be managed with concomitant NSAID 
administration, it is worthwhile to investigate how best to 
use NSAIDs during transition from the previous to the new 
formulation of sc IFN beta-1a.
Here we present results from the TRANSition From 
prEvious to new formulation of Rebif® (TRANSFER) study. 
This was designed to assess patient satisfaction in patients 
with relapsing MS transitioning from the original to the new 
formulation of sc IFN beta-1a. An additional objective was 
to provide physicians with recommendations on how best 
to manage the transition to the new formulation through the 
use of concomitant ibuprofen.
Methods
The TRANSFER study was a randomized, multicenter, 
two-arm, open-label, phase IIIb study, carried out at 
17 centers in France and Germany. The primary objective was 
to assess patient satisfaction, as measured by the Multiple 
Sclerosis Treatment Concerns Questionnaire (MSTCQ),11 
with particular regard to FLS, during the first 4 weeks after 
transition from the previous formulation of sc IFN beta-1a 
to the new formulation, in two groups: patients receiving 
ibuprofen preventatively, and patients receiving ibuprofen 
PRN. Patients aged 18–60 years with relapsing MS, were 
eligible for inclusion in the study if they had an Expanded 
Disability Status Scale score 5.5 at entry, and had been 
administering sc IFN beta-1a for at least 6 months prior to 
enrollment, using the Rebiject IITM (Merck Serono S.A. – 
Geneva, Switzerland) autoinjection device. Exclusion criteria 
included secondary progressive MS without superimposed 
relapses (according to the licensed indication of sc IFN 
beta-1a), the use of any other injectable medications during 
or after the week prior to screening, the administration of 
any immunomodulatory MS therapy in addition to sc IFN 
beta-1a in the 3 months prior to enrollment (combination 
therapy), a history of chronic pain syndrome, the occurrence 
of FLS due to any cause in the week prior to baseline, and 
contraindication to ibuprofen.
The duration of the trial was approximately 10 weeks, 
including a period of up to 2 weeks between the screening and 
baseline visits. Four visits were scheduled, beginning with the 
screening visit (Figure 1). The 4-week treatment period began 
with the baseline visit, when patients’ treatment with the 
previous formulation of sc IFN beta-1a 44 µg was replaced 
with the new formulation of sc IFN beta-1a 44 µg to be taken 
on the same 3 days each week. Laboratory assessments were 
performed at the baseline visit. Patients were required to 
complete a diary card, detailing any FLS, and reporting the 
use of any concomitant therapy. Diary data were collected 
between visits 2 and 4. The MSTCQ was self-administered 
by patients at the baseline visit and again 4 weeks later, at 
the end of the treatment period, when clinical and laboratory 
examinations were also performed. The treatment period was 
followed by a 4-week safety follow-up period, at the end of 
which a clinical examination and laboratory assessments 
were performed.
At the baseline visit, patients were randomized in a 
1:1 ratio to receive either ibuprofen preventatively or 
ibuprofen PRN, in addition to the new formulation of 
sc IFN beta-1a. Randomization was performed using sealed 
envelopes, and the centrally prepared randomization list was 
kept by an independent clinical research organization. Patients 
in the preventative ibuprofen (PI) group, were required to take 
ibuprofen, 400 mg orally, 30–60 minutes prior to each injection 
of the new formulation of sc IFN beta-1a. They also had the 
option of taking 2 additional 400-mg doses of ibuprofen at 
6-hour intervals if required, within 24 hours of injection. 
Patients randomized to receive ibuprofen PRN (IPRN group) Patient Preference and Adherence 2010:4 129
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were required not to take ibuprofen before injection, but had 
the option of taking ibuprofen 400 mg after injection if FLS 
occurred and were bothersome, with two further 400-mg doses 
permitted at 6-hour intervals within 24 hours of injection. For 
both groups, the maximum permitted total dose of ibuprofen 
per 24 hours was 1200 mg.
The primary study endpoint was the score of the FLS 
  component of the MSTCQ at week 4. Secondary endpoints 
were week 4 scores on the following subscales of the MSTCQ: 
total score, injection-system satisfaction, ISRs, and global 
side-effects. Tertiary endpoints were assessments of AEs 
and serious AEs (SAEs), laboratory assessments (including 
chemistry, thyroid function, and hematology), physical 
examination (including vital signs), and documentation 
of concomitant medications and procedures. The study 
was conducted in compliance with the ethical principles 
of the Declaration of Helsinki (1996 amendment) and 
with European regulatory requirements. All patients were 
required to provide written informed consent, which was 
obtained from each patient prior to the conduct of any 
trial-related procedures not routinely performed as part of 
the patient’s care.
The MSTCQ
The MSTCQ is a validated 20-item patient questionnaire 
developed to address patient concerns with IFN-beta 
  treatment that are not related to efficacy. It has two 
domains: injection-system satisfaction and side effects. The 
side-effects domain comprises 3 subscales: ISRs, global 
side effects, and FLS.11 All questions in the MSTCQ have a 
5-point response choice, with lower total scores indicating 
better outcomes.
Analysis populations and statistical 
methodology
The intent-to-treat (ITT) population was defined as all patients 
who underwent randomization. The safety population was 
defined as all patients receiving 1 dose of sc IFN beta-1a, 
and the per-protocol population was defined as all patients 
in the ITT population, excluding those who had 1 major 
protocol deviation. ‘All patients’ denotes all patients who 
provided informed consent. As this study was not hypothesis 
testing, only descriptive statistics are reported.
Effect sizes were calculated to reflect an estimate of 
clinically meaningful differences in MSTCQ scores between 
baseline and week 4. These effect sizes were calculated as 
mean change from baseline/standard deviation at baseline.12 
Effect sizes were classified as follows: a value 0.2, 0.5: 
small effect; a value 0.5, 0.8: moderate effect; a value 
0.8: large effect.11 Positive or negative values in effect size 
indicate only the direction of the change in score. A negative 
change in MSTCQ score indicates an improvement.
Results
Patients
A total of 123 patients gave informed consent; 117 were 
included in the trial and randomized to the PI (n = 60) or 
the I PRN (n = 57) group. Of the 117 patients enrolled, 
Randomization
Screening
Assessments
MSTCQ
Labs
Clinical
New formulation of
sc IFN beta-1a plus
preventative ibuprofen
New formulation of
sc IFN beta-1a
plus ibuprofen PRN
Time (weeks)
4-week safety extension
for new formulation of
sc IFN beta-1a Patients treated with
original formulation
of sc IFN beta-1a
–2 –2 –2 4 8 0
Figure 1 Study design.
Notes: The original formulation of sc IFN beta-1a contains fetal bovine serum (FBS) and human serum albumin (HSA) as excipients. The new formulation of sc IFN beta-1a 
is free from FBS and HSA.
Abbreviations: MSTCQ, Multiple Sclerosis Treatment Concerns Questionnaire; PRN, pro re nata (as needed); sc IFN beta-1a, subcutaneous interferon beta-1a.Patient Preference and Adherence 2010:4 130
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109 (93.2%) completed the study. Four patients (6.7%) in the 
PI group withdrew prematurely: 3 due to protocol violations 
and 1 withdrew consent. Four patients (7.0%) in the I PRN 
group withdrew from the study: 1 patient was lost to follow-up, 
1 patient withdrew due to AEs (injection-site hematoma), and 
2 others withdrew due to ‘other’ reasons (‘severe migraine’, 
and an ‘MS attack treated with steroids’, respectively).
Patient baseline demographic characteristics were largely 
similar between the two groups (Table 1), although there was a 
higher proportion of female patients in the PI group than in the 
I PRN group (80.0% and 70.2%, respectively). Prior exposure to 
the previous formulation of sc IFN beta-1a was slightly higher in 
the I PRN group. Median duration of treatment was 26.5 (range 
4–97) months in the PI group and 33.9 (range 4–96) months 
in the I PRN group. Four patients randomized to the PI group 
mistakenly took ibuprofen PRN on study day 1, and another 
4 patients randomized to the I PRN group mistakenly took 
preventative ibuprofen on study day 1. These 8 patients were 
therefore included in the safety population according to how 
they administered ibuprofen treatment on study day 1.
The median number of additional doses of ibuprofen 
taken during the treatment period was 1 (range 0–31) in 
the PI group. Patients in the I PRN group took a median of 
2 (range 0–24) optional doses of ibuprofen.
MSTCQ results
There was no clinically meaningful change from baseline 
to week 4 in the FLS domain score in either treatment arm. 
The mean total MSTCQ score improved between baseline 
and week 4 in both treatment groups and the mean scores 
for ISRs showed an improvement in patients’ perception 
of ISRs from baseline to week 4 in both groups. The mean 
global side-effects scores showed no worsening in patients’ 
  perception of side effects from baseline to week 4 in 
either group, whereas mean scores in the injection-system 
  satisfaction domain improved from baseline to week 4 in both 
treatment groups. The mean changes from baseline in the 
MSTCQ total score and in the individual MSTCQ domains 
and subscales are shown in Table 2. Where improvements 
were seen, the effect sizes were small to moderate.
Safety during the 4-week  
treatment period
A total of 79/116 (68.1%) patients experienced an AE in at least 
one of the prespecified AE categories of interest (Table 3). Most 
AEs were of mild or moderate severity. The AE reported most 
commonly was FLS: by 66.1% of patients in the PI group and 
by 66.7% of patients in the I PRN group. ISRs were reported 
in a lower proportion of patients in the I PRN group than in the 
PI group (3.5% and 6.8%, respectively). Table 4 shows the most 
common AEs during the 4-week treatment period. The safety 
data show that AEs were consistent with the established safety 
profile of sc IFN beta-1a. Fatigue, nausea, and injection-site 
erythema were more common in the PI group than in the IPRN 
group. Arthralgia, myalgia, migraine, and nasopharyngitis were 
all more common in the IPRN group than in the PI group. One 
patient in the IPRN group (1.8%) withdrew from treatment due 
to injection-site hematoma, and 1 patient (1.7%) in the PI group 
reported mild abdominal pain as an SAE. This patient was 
hospitalized for 4 days, after which the pain resolved and study 
treatment continued uninterrupted. The investigator assessed 
the event as unlikely to be related to sc IFN beta-1a treatment 
and indicated that it may have been psychosomatic in origin.
Safety during the 4-week safety  
extension period
During the 4-week safety extension period, at least one AE 
was reported by a total of 73/116 (62.9%) patients. A higher 
Table 1 Patient baseline demographics and disease characteristics
Patient characteristic Preventative  
ibuprofen (n = 60)
Ibuprofen  
PRN (n = 57)
Total (n = 117)
Age (years) Mean ± SD 41.7 ± 8.4 41.5 ± 8.9 41.6 ± 8.6
Median (range) 42.0 (23–60) 43.9 (20–58) 43.0 (20–60)
Sex Male 12 (20.0%) 17 (29.8%) 29 (24.8%)
Female 48 (80.0) 40 (70.2) 88 (75.2)
Number of MS relapses during 24 months Mean ± SD 1.4 ± 1.3 1.0 ± 1.1 1.2 ± 1.3
Median (range) 1.0 (0.0–5.0) 1.0 (0.0–5.0) 1.0 (0.0–5.0)
EDSS score Mean ± SD 2.3 ± 1.5 2.0 ± 1.3 2.2 ± 1.4
Median (range) 2.0 (0.0–5.5) 2.0 (0.0–5.5) 2.0 (0.0–5.5)
Exposure to sc IFN beta-1a, months Mean ± SD 31.0 ± 23.7 36.8 ± 26.7 33.8 ± 25.3
Median (range) 26.5 (4.0–97.0) 33.9 (4.0–96.0) 29.4 (4.0–97.0)
Abbreviations: EDSS, Expanded Disability Status Scale; IFN, interferon; MS, multiple sclerosis; PRN, pro re nata; sc, subcutaneous; SD, standard deviation.Patient Preference and Adherence 2010:4 131
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proportion of patients in the PI group (71.2%) than in the 
IPRN group (54.4%) reported AEs. The AEs reported most 
commonly during this period were FLS, headache, and 
fatigue, being reported by 46.6%, 22.4%, and 12.1% of 
all patients, respectively. FLS occurred in a slightly higher 
proportion of patients in the PI group (52.5%) than in the 
IPRN group (40.4%). No patient experienced an SAE during 
the safety extension period, and no AEs led to study or IFN 
beta-1a treatment discontinuation.
Discussion
This randomized, open-label, phase IIIb study, assessed 
  satisfaction in patients with relapsing MS when transitioning 
from the original formulation of sc IFN beta-1a to a new 
formulation produced without FBS and without HSA as 
excipiens.
There was no clinically meaningful change from baseline 
in the score for the FLS component of the MSTCQ in either 
treatment group, indicating that FLS are not an obstacle 
in the transition to the new formulation of sc IFN beta-1a, 
and that any FLS that occur during transition can be easily 
managed with ibuprofen taken either preventatively or PRN. 
Although FLS were experienced by approximately two-thirds 
of patients in each group at some point during the study, the 
optional use of ibuprofen was low in both groups, showing 
that when FLS appeared, patients seldom considered them 
sufficiently bothersome to require treatment.
Both treatment groups showed improvements from 
  baseline to week 4 in the mean MSTCQ total score and 
  injection-system satisfaction score, with a small overall 
effect size in each case, and an improvement in the mean 
MSTCQ ISR score, with a moderate effect size. There 
was no change from baseline in the mean MSTCQ global 
side-effects score in either group. These results indicate that 
patients transitioning from the previous formulation of sc 
IFN beta-1a to the new formulation, were either equally or 
more satisfied with their new treatment.
A lower proportion of patients experienced FLS during 
the 4-week safety extension period (46.6%) than during 
the treatment period (66.4%). During the safety extension 
period, FLS were experienced by a higher proportion of 
patients randomized to preventative ibuprofen (52.5%) than 
those randomized to ibuprofen PRN (40.4%). However, it is 
unclear whether this was due to an actual higher incidence 
rate of FLS in the ‘previously preventative’ patients following 
a switch to PRN use of ibuprofen, or whether FLS were 
  perceived more acutely by these patients following the switch 
in ibuprofen regimen.Patient Preference and Adherence 2010:4 132
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Table 3 Prespecified adverse events during the 4-week treatment period (safety population)
Treatment
Preventative ibuprofen (n = 59) Ibuprofen PRN (n = 57) Total (n = 116)
Patients n (%) n (%) n (%)
Adverse event  
Any prespecified adverse event 40 (67.8) 39 (68.4) 79 (68.1)
Depression and suicidal ideation 0 (0.0) 1 (1.8) 1 (0.9)
Flu-like symptoms 39 (66.1) 38 (66.7) 77 (66.4)
Injection-site reactions 4 (6.8) 2 (3.5) 6 (5.2)
Skin rashes 2 (3.4) 0 (0.0) 2 (1.7)
Thyroid disorders 2 (3.4) 0 (0.0) 2 (1.7)
Abbreviation: PRN, pro re nata.
Table 4 Most common adverse events during the 4-week treatment period*
Adverse event Treatment
Preventative ibuprofen Ibuprofen PRN Total
Patients  
(n = 59)
Events  
(n = 313)
Patients  
(n = 57)
Events  
(n = 272)
Patients  
(n = 116)
Events (n = 585)
Patients, n (%) Events, n (%) Patients, n (%) Events, n (%) Patients, n (%) Events, n (%)
Flu-like symptoms 39 (66.1) 182 (58.1) 38 (66.7) 170 (62.5) 77 (66.4) 352 (60.2)
Headache 22 (37.3) 41 (13.1) 16 (28.1) 33 (12.1) 38 (32.8) 74 (12.6)
Fatigue 15 (25.4) 36 (11.5) 7 (12.3) 10 (3.7) 22 (19.0) 46 (7.9)
Myalgia 3 (5.1) 3 (1.0) 5 (8.8) 17 (6.3) 8 (6.9) 20 (3.4)
Chills 4 (6.8) 5 (1.6) 4 (7.0) 5 (1.8) 8 (6.9) 10 (1.7)
Arthralgia 2 (3.4) 2 (0.6) 4 (7.0) 10 (3.7) 6 (5.2) 12 (2.1)
Back pain 3 (5.1) 3 (1.0) 2 (3.5) 2 (0.7) 5 (4.3) 5 (0.9)
Migraine 0 (0.0) 0 (0.0) 4 (7.0) 5 (1.8) 4 (3.4) 5 (0.9)
Nasopharyngitis 2 (3.4) 2 (0.6) 3 (5.3) 3 (1.1) 5 (4.3) 5 (0.9)
Pyrexia 2 (3.4) 4 (1.3) 1 (1.8) 1 (0.4) 3 (2.6) 5 (0.9)
Vertigo 0 (0.0) 0 (0.0) 3 (5.3) 3 (1.1) 3 (2.6) 3 (0.5)
Injection-site pain 1 (1.7) 2 (0.6) 1 (1.8) 1 (0.4) 2 (1.7) 3 (0.5)
Abdominal pain 1 (1.7) 1 (0.3) 1 (1.8) 1 (0.4) 2 (1.7) 2 (0.3)
Antithyroid antibody  
positive
2 (3.4) 2 (0.6) 0 (0.0) 0 (0.0) 2 (1.7) 2 (0.3)
Diarrhea 1 (1.7) 1 (0.3) 1 (1.8) 1 (0.4) 2 (1.7) 2 (0.3)
Injection-site erythema 2 (3.4) 2 (0.6) 0 (0.0) 0 (0.0) 2 (1.7) 2 (0.3)
Nausea 2 (3.4) 2 (0.6) 0 (0.0) 0 (0.0) 2 (1.7) 2 (0. 3)
*Occurring in 1% of patients. PRN, pro re nata.
The changes in MSTCQ scores for ISRs and injection 
system satisfaction following treatment transition indicate 
improved patient rating of ISRs and the injection process 
with the new formulation. Indeed, this was one of the key 
objectives for which the new formulation of sc IFN beta-1a 
was developed. The improvement in the rating of injection 
system satisfaction must actually reflect the difference in 
patient perception due to the change in formulation, because 
all patients used the same injection device both before and 
after the transition.
The overall incidence of FLS during the treatment 
period was higher than in the sc IFN beta-1a arms of 
the EVIDENCE and REGARD studies of the previous 
  formulation, but lower than that in the open-label, single-arm 
study of the new formulation of sc IFN beta-1a, which did 
not mandate ibuprofen treatment. The incidence of ISRs in 
the present study was considerably lower than those reported 
for the previous studies mentioned above. However, these 
  inconsistencies are not surprising, as no direct comparison 
can be made with any of these trials because of differences 
in study design and duration.
Conclusions
Overall in this study, patient ratings of ISRs improved and 
patients reported either equal or greater levels of satisfaction 
with the new formulation of IFN beta-1a compared with the 
original formulation. As these patients had received stable 
treatment with the previous formulation for at least 6 months Patient Preference and Adherence 2010:4
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(and the majority for more than 2 years), a reasonable level 
of treatment satisfaction with the previous formulation is 
implicit. Patient satisfaction with treatment is important in 
the period following a therapy adjustment, when patients 
may be at heightened risk of discontinuation. In addition, 
the transition to the new formulation was well tolerated and 
FLS, when they occurred, were mild and rarely considered 
to be sufficiently bothersome to warrant treatment. However, 
if required, such symptoms were easily managed with 
  ibuprofen, administered either preventatively or PRN.
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